Eli Lilly Secures FDA Approval for Omvoh® to Treat Moderately to Severely Active Crohn’s Disease

 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for...

January 16, 2025 | Thursday | News
Advanced Genomics APAC Partners with Cancer Precision Medicine to Launch GALEAS™ Bladder Cancer Screening Test in Japan

Advanced Genomics APAC Co., Ltd. (hereinafter referred to as "Advanced Genomics APAC," headquartered in Taiwan, Managing Director: Andy Chang) is pl...

January 15, 2025 | Wednesday | News
Windward Bio Launches with $200M Series A Financing to Develop Breakthrough Immunology Treatments

Windward Bio, a private, clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases, a...

January 12, 2025 | Sunday | News
Japan-Based Meiji Seika Pharma Invests $20 Million in U.S.-Based MPM BioImpact to Drive Innovations in Virology and Biotech

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Daikichiro Kobayashi, hereinafter “Meiji”) announce...

January 13, 2025 | Monday | News
FDA Accepts Revised sNDA for Astellas' IZERVAY™ in Treatment of Geographic Atrophy

 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced the U.S. Food and Drug Administration (FDA) a...

January 09, 2025 | Thursday | News
Primo Biotechnology Partners with SHINE Technologies to Distribute Ilumira® in Asia-Pacific

Primo Biotechnology (“Primo”) announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear ...

January 09, 2025 | Thursday | News
VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Approved by Japan’s MHLW for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated wi...

December 31, 2024 | Tuesday | News
Takeda Receives Japanese Regulatory Approval for HYQVIA® in Primary and Secondary Immunodeficiency Disorders

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Takeda received regulatory approval for HYQVIA® [Immune Globulin Infusion 10%...

December 31, 2024 | Tuesday | News
Japan Approves VYVDURA® for At-Home Self-Injection in gMG and CIDP, Setting a Global Benchmark

VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfoli...

December 27, 2024 | Friday | News
Axcelead DDP and Astellas Partner in Japan to Advance Targeted Protein Degrader Discovery

Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced that it has entered into a drug discovery se...

December 26, 2024 | Thursday | News
Fujirebio and Eisai Forge Partnership to Advance Blood-Based Diagnostics for Neurodegenerative Diseases

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Cha...

December 26, 2024 | Thursday | News
Regeneron’s EYLEA HD® Achieves Key Milestone in Phase 3 QUASAR Trial for Macular Edema Due to Retinal Vein Occlusion

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD® (af...

December 18, 2024 | Wednesday | News
Eli Lilly's Omvoh® (Mirikizumab) Receives Positive CHMP Opinion for Crohn’s Disease in the EU

Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

December 16, 2024 | Monday | News
Mexico Approves Eisai and Biogen’s LEQEMBI for Early Alzheimer’s Disease Treatment

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...

December 09, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close